🇺🇸 FDA
Pipeline program

Lanadelumab

TAK-743-3001

Phase 3 small_molecule completed

Quick answer

Lanadelumab for Angioedema is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Angioedema
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials